
CSTL Stock Forecast & Price Target
CSTL Analyst Ratings
Bulls say
Castle Biosciences Inc. is experiencing significant growth in its TissueCypher test, with test volume expanding by 92% year-over-year and 23% quarter-over-quarter in 2Q25, likely aided by a strengthened sales force. The company has also improved the gross margin of the TissueCypher test, achieving an impressive 77% gross margin in Q3, which indicates robust profitability. With ongoing expansions in sales and a mature gastrointestinal sales force anticipated by the second half of 2025, Castle Biosciences is positioned for continued revenue growth in its gastrointestinal diagnostics segment.
Bears say
Castle Biosciences Inc. faces a negative outlook due to concerns over its expected revenue multiples, particularly for its dermatology and DecisionDx-UM tests, which are anticipated to be significantly lower than those for the TissueCypher product. Management highlighted a lack of clinician awareness regarding these tests as a critical barrier to market penetration, suggesting that current growth may be hindered by insufficient adoption in key segments. Additionally, while the stock may seem undervalued based on conservative estimates, the persistent challenges in clinician engagement and product awareness could limit future revenue growth and investor confidence.
This aggregate rating is based on analysts' research of Castle Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
CSTL Analyst Forecast & Price Prediction
Start investing in CSTL
Order type
Buy in
Order amount
Est. shares
0 shares